Cannabis Compounds Reduced Spasticity and Tremor in an MS Mouse Model, Published in Nature | Research

The takeaway

In a landmark Nature study, multiple cannabinoid compounds reduced both spasticity and tremor in mice with an MS-like disease, while blocking cannabinoid receptors worsened symptoms, suggesting the body's own endocannabinoid system actively controls these symptoms.

Read this if you want to understand the strongest preclinical evidence for why cannabis helps MS spasticity and tremor.

Blocking cannabinoid receptors worsened spasticity, revealing endocannabinoid tone

What the researchers found

Using a mouse model of MS (chronic relapsing experimental allergic encephalomyelitis) that produces spasticity and tremor similar to human MS, researchers tested multiple cannabinoid compounds.

Four different cannabinoid receptor agonists, including THC, all quantitatively reduced both tremor and spasticity in the diseased mice. This was the first objective, quantitative demonstration in an animal model.

The more revelatory finding came from the antagonist experiments. When cannabinoid receptors were blocked (particularly CB1), spasticity and tremor worsened. This meant the body's own endocannabinoid system was already actively working to control these symptoms. Cannabinoid drugs were not introducing a new effect but rather augmenting an existing natural defense mechanism.

This provided the scientific rationale for MS patients' reports that cannabis helped their symptoms and established a framework for developing more selective cannabinoid treatments.

Why it matters

Published in Nature, one of science's most prestigious journals, this study provided the strongest preclinical evidence yet for cannabis in MS. The finding that blocking cannabinoid receptors worsened symptoms was particularly important because it revealed an active endocannabinoid tone controlling spasticity, a previously unknown function.

The numbers in context

Four cannabinoid agonists tested, all effective. Two antagonists tested: CB1 blockade notably worsened symptoms. Both tremor and spasticity were quantitatively measured and improved.

How the study worked

Controlled animal study using CREAE mice (MS model). Tested four cannabinoid agonists (R(+)-WIN 55,212, THC, methanandamide, JWH-133) and two antagonists (SR141716A targeting CB1, SR144528 targeting CB2). Spasticity and tremor were quantitatively measured.

What this study cannot tell us

Mouse model of MS, not human MS. CREAE captures some but not all features of human MS. Quantitative measures in mice may not predict clinical significance in humans. Short-term drug effects measured without long-term follow-up.

How to read the evidence

Published in Nature with rigorous quantitative methods and both agonist and antagonist approaches. Among the strongest preclinical evidence available, though still an animal model.

When this study was published

Published in 2000 in Nature. This study directly motivated the clinical trials that led to nabiximols (Sativex) approval for MS spasticity.

The bigger picture

This Nature paper was a pivotal moment for cannabinoid medicine. It moved the MS-cannabis conversation from anecdotal patient reports to rigorous, quantitative preclinical evidence and directly motivated the clinical trials that led to nabiximols (Sativex) approval for MS spasticity.

Questions still open

Does the endocannabinoid tone controlling spasticity exist in human MS? Would chronic cannabinoid treatment maintain efficacy or would tolerance develop? Which cannabinoid receptor type is the better therapeutic target?

Common questions

Does cannabis help MS symptoms?

In this mouse model, multiple cannabinoid compounds reduced both spasticity and tremor. Blocking cannabinoid receptors made symptoms worse, suggesting the body already uses endocannabinoids to control these symptoms.

Why was this study important?

Published in Nature, it was the first quantitative demonstration that cannabinoids reduce MS-like spasticity in an animal model and revealed that the endocannabinoid system actively controls these symptoms.

Read the original research

Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Nature, 404(6773), 84-7

View on PubMed ↗

Citation

Baker, D; Pryce, G; Croxford, J L; Brown, P; Pertwee, R G; Huffman, J W; Layward, L. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model.. Nature, 404(6773), 84-7.